All News
New Oral Option for axSpA: Filgotinib for Radiographic and Non-Radiographic Disease
The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?
Read Article
INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease
B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
Read Article
Obinutuzumab drives histologic remission in lupus nephritis
At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.
Read Article
SLE Pipeline of New Therapies
Dr. Andrea Fava, EULAR 2026 in London.
https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF
Dr. John Cush RheumNow ( View Tweet)
#TYK2i #deucravacitinib
#RCT in #SLE
LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts
#POS0695 #EULAR2026 @RheumNow https://t.co/vtrMYrFmJ9
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow
https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
This study evaluated the risk of flares after sustained drug-free rem in SLE.
% of pts w/ reported flares w/n yrs in rem:
48.6% at 2yrs
42.3% at 3yrs
35.2% at 5 yrs
Mucocut, msk, renal & immuno - ⬆️affected domain
Reassess pts regularly.
POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh
sheila RHEUMarampa ( View Tweet)
#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow https://t.co/9COyXbghkl
Mrinalini Dey DrMiniDey ( View Tweet)
Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246
Jiha Lee JihaRheum ( View Tweet)
SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
Dr. John Cush RheumNow ( View Tweet)
#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort:
-enriched in Black patients
-poor response to B-cell depletion inc. Obi
-non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab
-High ferritin = flare @RheumNow https://t.co/3uDMigY8i2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission?
Data from 194 patients from the SELECT-AXIS2 RCT:
▶️ Remission maintained in 1/4 at48 weeks
POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux
Nelly ZIADE 🍀 Nellziade ( View Tweet)
LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstr LB0003
Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered.
RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD.
Curious about long term results and potential position in tx strategies
LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO
Links:
sheila RHEUMarampa ( View Tweet)
Abstr LB0004
CC312 is a CD19/CD3/CD28 tri-specific T cell engager and sustains SRI-4 responses beyond one year with rapid, deep B-cell depletion in autoimmune diseases. Not CAR-T. Not a conventional biologic. A T cell engager that redirects your own immune cells to deplete B https://t.co/rTs3Rg7BPe
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
CAR-T without the CAR-T risks?
AB-101, an off-the-shelf NK cell therapy + RTX, delivered in refractory RA, Sjögren, and SSc (n=31): RA ACR50 71%, SSc mRSS -9.5, SjD ClinESS DAI -8.6 at 6 mo. Outpatient delivery without CAR-T associated AEs? @RheumNow #EULAR2026 LB0003 https://t.co/xi6ZdLwHcN
Jiha Lee JihaRheum ( View Tweet)
